Published July 15, 2011 | Version v1
Journal article

Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group

  • 1. Department of Radiation Oncology, Stanford University, Stanford, CA (United States)
  • 2. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
  • 3. Department of Surgery, University of Pittsburg School of Medicine, Pittsburg, PA (United States)
  • 4. Division of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA (United States)
  • 5. Department of Orthopedics, British Columbia Children's Hospital, Vancouver, BC (Canada)
  • 6. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE (United States)

Description

Purpose: To evaluate the incidence and prognostic factors for regional failure, with attention to the in-transit pathways of spread, in children with nonmetastatic rhabdomyosarcoma of the extremity. Methods and Materials: The Intergroup rhabdomyosarcoma studies III, IV-Pilot, and IV enrolled 226 children with rhabdomyosarcoma of the extremity. Failure at the in-transit (epitrochlear/brachial and popliteal) and proximal (axillary/infraclavicular and inguinal/femoral) lymph nodes was evaluated. The median follow-up for the surviving patients was 10.4 years. Results: Of the 226 children, 55 (24%) had clinical or pathologic evidence of either in-transit and/or proximal lymph node involvement at diagnosis. The actuarial 5-year risk of regional failure was 12%. The prognostic factors for poor regional control were female gender and lymph node involvement at diagnosis. In the 116 patients with a distal extremity primary tumor, 5% had in-transit lymph node involvement at diagnosis. The estimated 5-year incidences of in-transit and proximal nodal failure was 12% and 8%, respectively. The in-transit failure rate was 0% for patients who underwent radiotherapy and/or underwent lymph node sampling of the in-transit nodal site but was 15% for those who did not (p = .07). However, the 5-year event-free survival rate did not differ between these two groups (64% vs. 55%, respectively, p = .47). Conclusion: The high incidence of regional involvement necessitates aggressive identification and treatment of regional lymph nodes in patients with rhabdomyosarcoma of the extremity. In patients with distal extremity tumors, in-transit failures were as common as failures in more proximal regional sites. Patients who underwent complete lymph node staging with appropriate radiotherapy to the in-transit nodal site, if indicated, were at a slightly lower risk of in-transit failure.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2010.03.050

Additional details

Additional titles

Augmented title (English)
Rhabdomyosarcoma; Regional failure; In-transit nodes; Radiotherapy; Extremity

Identifiers

DOI
10.1016/j.ijrobp.2010.03.050;
PII
S0360-3016(10)00613-9;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
80
Journal Issue
4
Journal Page Range
p. 1151-1157
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
43066007
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHILDREN; DIAGNOSIS; HAZARDS; LYMPH NODES; NEOPLASMS; RADIOTHERAPY
Descriptors DEC
AGE GROUPS; ANIMALS; DISEASES; LYMPHATIC SYSTEM; MAMMALS; MAN; MEDICINE; NUCLEAR MEDICINE; PRIMATES; RADIOLOGY; THERAPY; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.